Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era
ConclusionHBeAg-positive patients receiving combination therapy have a 17-fold higher risk of HBVr than HBeAg-negative patients with PD-1 inhibitors monotherapy.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Antiviral Therapy | Cancer | Cancer & Oncology | Hepatitis | Hepatitis B | Immunotherapy | Study